| Date | Title | Description | |
|---|---|---|---|
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
| 07 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 | Download |
| 31 Jan 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 | Download |
| 24 Jan 2022 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 20 Feb 2018 | Información sobre resultados | ROVI releases the presentation related to the full year 2017 results | Download |
| 20 Feb 2018 | Información sobre resultados | ROVI releases the press release related to the full year 2017 results | Download |
| 20 Feb 2018 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2017 annual report regarding remuneration of the members of the Board of Directors | Download |
| 20 Feb 2018 | Informe Anual de Gobierno Corporativo | ROVI releases the 2017 Annual Corporate Governance Report | Download |
| 20 Feb 2018 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |